KIORA PHARMACEUTICALS, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
KIORA PHARMACEUTICALS, INC. (KPRX) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-06-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $16.00M.
- KIORA PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $0.00.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $16.00M 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $16.00M 10-Q · filed 2025-11-07 | $16.00M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $16.00M 10-Q · filed 2025-08-08 | $16.00M derived: sum of 3 quarters · filed 2025-08-08 | $16.00M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $16.00M 10-Q · filed 2025-05-09 | $16.00M derived: sum of 2 quarters · filed 2025-05-09 | $16.00M derived: sum of 3 quarters · filed 2025-05-09 | $16.00M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |